Post-ERCP bowel evisceration in a liver transplant recipient previously treated with atezolizumab-bevacizumab: first report

Abstract

Hepatocellular carcinoma (HCC) treatment increasingly involves liver transplantation (LT), often after downstaging therapies. Atezolizumab, a PD-L1 inhibitor, combined with bevacizumab, an anti-VEGF agent, is widely used, showing high response rates pre-transplant. However, bevacizumab impairs angiogenesis and can significantly increase the risk of wound dehiscence, infection, and delayed healing after major surgery, including LT.